PMID: 7538976May 16, 1995Paper

CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy

International Journal of Cancer. Journal International Du Cancer
M B YacyshynB M Longenecker

Abstract

Lymphocyte activation markers CD69 and HLA-DR were studied in metastatic breast and ovarian cancer patients who received active specific immunotherapy (ASI) using cancer vaccines containing the synthetic tumor-associated antigen sialyl-Tn or the Thomsen-Friedenreich antigen conjugated to KLH plus DETOX adjuvant. Breast cancer patients who showed prolonged survival following ASI had lower numbers of total CD69+ and CD4+CD69+ cells prior to ASI compared to patients who died. However, following ASI, the surviving patients showed an increase in CD69+ and CD4+CD69+ cells and the deceased patients showed a decrease. A greater than 50% increase in the percentage of cells bearing the activation marker CD69 is associated with an increase in survival in both ovarian and breast cancer patients. In the surviving breast cancer patients there was a significant decrease in the percentage of non-B lymphocyte HLA-DR+ (CD20-HLA-DR+) cells following cyclophosphamide treatment. A strong positive correlation was found between lymphocyte populations CD20- HLA-DR+ and CD8+CD57+, a putative suppressor cell population. Breast cancer patients who showed a greater than median decrease in CD20-HLA-DR+ lymphocytes following cyclophosphamide treatment had a...Continue Reading

References

May 1, 1992·European Journal of Immunology·A G SantisF Sánchez-Madrid
Nov 1, 1988·Journal of Clinical Immunology·H W Ziegler-HeitbrockG Riethmüller
Jul 1, 1994·Immunology Today·W J Pichler, T Wyss-Coray
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·G D MacLeanB M Longenecker

❮ Previous
Next ❯

Citations

Dec 4, 2003·Journal of Structural Biology·Fabrice MoucheBridget Carragher
Jul 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Haruhiko NakamuraHarubumi Kato
Mar 16, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·H NakamuraH Kato
May 7, 1999·International Journal of Immunopharmacology·J W Hadden
Nov 2, 1999·Micron : the International Research and Review Journal for Microscopy·J R Harris, J Markl
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B MelicharR S Freedman
Mar 13, 2016·Biochimica Et Biophysica Acta·Joanne ChiaFrederic Bard
Dec 1, 2001·Expert Opinion on Biological Therapy·L A Holmberg, B M Sandmaier
Sep 18, 2014·The Cochrane Database of Systematic Reviews·Ninke LeffersHans W Nijman
Sep 11, 2018·The Cochrane Database of Systematic Reviews·Sterre T PaijensHans W Nijman
Nov 2, 2007·European Journal of Clinical Investigation·G KonjevićI Spuzić
Jun 10, 2021·Oncoimmunology·Annat RaiterRinat Yerushalmi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.